What happened with AVLN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Avalyn Pharma Inc. is developing medicines that patients inhale to treat pulmonary fibrosis, a disease involving scarring of the lungs. Its business depends mainly on AP01, inhaled pirfenidone for progressive pulmonary fibrosis, and AP02, inhaled nintedanib for idiopathic pulmonary fibrosis. Both are in clinical trials; neither is approved for sale.
Avalyn has generated no revenue and funds development with capital raised from investors and borrowing. It needs further funding to advance its candidates. Future drug sales require successful clinical development and regulatory approval, followed by doctors prescribing the medicines and insurers covering them, or patients paying out of pocket.
The treatments use PARI’s eRapid Nebulizer System with eFlow Technology to deliver medicine to the lungs. Avalyn licenses the system exclusively for AP01 and holds an exclusive right to negotiate separate licenses for AP02 and AP03. It depends on PARI for device supply and plans to seek approval for the drug and device together.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Avalyn Pharma Inc.’s prospects depend on AP01 and AP02 succeeding clinically while facing Boehringer Ingelheim’s established fibrosis medicines and relying on access to PARI’s licensed nebulizer technology.
United Therapeutics is seeking to expand inhaled Tyvaso into idiopathic and progressive pulmonary fibrosis, putting it in competition with Avalyn’s inhaled treatments for those patients. Its reported positive Phase 3 TETON-1 and TETON-2 results and planned IPF approval filing are the developments to watch.
MannKind and Avalyn are developing competing inhaled treatments for idiopathic pulmonary fibrosis, both aiming to deliver medicine directly to the lungs. MannKind also earns manufacturing revenue and sales royalties from United Therapeutics’ Tyvaso DPI, so its IPF development news is more directly relevant to Avalyn than that existing revenue stream.
Insmed plans to study inhaled TPIP in idiopathic and progressive pulmonary fibrosis, bringing another potential treatment into the patient groups targeted by Avalyn’s AP01 and AP02. Watch the launch and progress of those TPIP studies, rather than sales of Insmed’s existing respiratory medicines.
Rein Therapeutics, Inc. competes with Avalyn to develop new treatments for pulmonary-fibrosis patients. It had no product-sales revenue through the fiscal year ended December 31, 2025, and says advancing LTI-03 depends on obtaining funding, making that funding important to watch.
AgomAb Therapeutics NV’s AGMB-447 targets the same idiopathic pulmonary fibrosis treatment market as Avalyn’s inhaled candidates. With no approved products or revenue through December 31, 2025, AgomAb’s AGMB-447 development progress—not current medicine sales—is the relevant signal for Avalyn.
Contineum Therapeutics, Inc. is developing pulmonary-fibrosis treatments that would compete with Avalyn’s candidates for the same patients. Its fibrosis-program news is the relevant comparison; the payment it received from J&J for rights to develop and sell PIPE-307 is a separate part of its business.
Bristol Myers Squibb’s Phase 3 admilparant program competes with Avalyn’s AP01 and AP02 in idiopathic pulmonary fibrosis drug development. Admilparant’s trial results are the concrete development to watch against Avalyn’s still-clinical inhaled treatments.
GRI Bio, Inc.’s oral GRI-0621 offers a competing investigational approach to Avalyn’s inhaled treatments for idiopathic pulmonary fibrosis. Watch its Phase 2 results for evidence on that oral alternative; GRI Bio does not expect product revenue before successful development, approval and commercialization.
Cumberland Pharmaceuticals Inc’s Phase 2 Vasculan program targets the same idiopathic pulmonary fibrosis patients as Avalyn’s AP02. Although Cumberland already sells branded prescription medicines, Vasculan’s trial progress is the part of its business that matters directly to this competition.
United Therapeutics Corp earningsUTHR
United Therapeutics' report will show whether inhaled Tyvaso is moving toward an IPF filing, bringing its treatment closer to some of the same patients targeted by Avalyn Pharma's inhaled candidates.
Look for an update on United Therapeutics' planned IPF filing for inhaled Tyvaso. Progress would bring an inhaled treatment with reported positive Phase 3 results closer to IPF patients, raising the bar for Avalyn Pharma's AP02 and other candidates; delay or no progress would make that pressure less immediate, but would not show that Avalyn's candidates work. The question is how close this competitor is to reaching the same patients.
Avalyn Pharma Inc. earningsThis company
Avalyn Pharma has no product sales, so this report will show whether it can advance AP01 and AP02 trials without using cash faster than its funding plan can support.
Read research and development spending and operating cash use alongside any reported progress in the AP01 and AP02 trials. Progress in both trials with manageable cash use would show that funding is translating into development; faster cash use without corresponding progress would mean the funding cushion is shrinking without comparable clinical gains. Lower spending paired with stalled trials could instead reflect slower development. The conclusion is whether Avalyn is turning its available capital into meaningful clinical progress.
